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OBJECTIVE
Using the 2016Medicare Part D coverage gap as an example, we explored effects of
increased out-of-pocket costs on adherence to branded dipeptidyl peptidase
4 inhibitors (DPP-4i) in patients without financial subsidies relative to subsidized
patients who do not experience increased spending during the gap. We also
explored seasonality of reinitiation, because discontinuers may be more likely to
reinitiate in January when benefits reset.
RESEARCH DESIGN AND METHODS
We identified DPP-4i or sulfonylurea initiators, aged ‡66 years, from a 20% sample
of 2015–2016 Medicare claims. Difference-in-differences Poisson regression was
used to compare adherence before and after entering the coverage gap between
nonsubsidizedandsubsidizedpatients.Amongdiscontinuers,monthlyhazardratios
(HRs) for reinitiation relative to January 2016 were derived with Cox models. As
a second control, we repeated analyses using sulfonylureas, generic low-cost
alternatives.
RESULTS
In 2016, 8,096 subsidized and 6,173 nonsubsidized DPP-4i initiators entered the
coverage gap. For nonsubsidized patients, copayment in the coverage gap was
45% ($227 per DPP-4i prescription), and adherence decreased from 68.4% to 49.0%
after gap entry. Accounting for adherence differences in subsidized patients,
nonsubsidized patients demonstrated reduced adherence to DPP-4i (difference-
in-difference: 216.9%; 95% CI 218.7%, 215.1%) but not sulfonylureas (21.6%;
95% CI 23.4%, 0.2%). Reinitiation was lowest in the months before January (HR
0.4–0.5) among nonsubsidized DPP-4i patients, demonstrating a strong seasonal
pattern.
CONCLUSIONS
Increased out-of-pocket costs negatively affect adherence and reinitiation of
branded antihyperglycemic drugs among patients without financial subsidies.
Despite closure of the coverage gap, affordability remains a concern given increasing
list prices for many drugs on Medicare and the growing use of deductibles and
coinsurance by commercial health plans.
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More than 25% of older adults (age$65)
in theU.S. have type 2 diabetes. Diabetes
is responsible for a large economic bur-
den, with estimated medical costs of
nearly $10,000 directly attributable to
diabetes care per patient annually, much
ofwhich is paid by theMedicare program
(1,2). Antihyperglycemic treatment is an
important component of diabetes man-
agement, with better treatment adher-
ence being associated with decreases in
HbA1c, lower mortality, and lower health
care expenditures (3–7).
The supplemental Medicare Part D
program, which provides prescription
drug coverage toMedicare beneficiaries,
has .43 million beneficiaries enrolled
(8). A unique and long-criticized compo-
nent of this program was the coverage
gap (9), where in 2006 beneficiaries with
drug spending over a certain threshold
were required to pay full price for their
drugs until they reached “catastrophic”
spending levels. With the implementa-
tionof theAffordableCareAct, beginning
in 2011, the amounts that patients were
responsible for paying during the cover-
age gap started to decrease from 100%
of a drug’s price in 2010 to 25% in 2020
(9,10).With the passage of theBipartisan
Budget Act, the coverage gap closed 1
year earlier than planned (cost sharing
for branded drugs decreased to 25% in
2019) (11,12).
The Part D benefit design with the in-
creased out-of-pocket expenditure dur-
ing the coverage gap is similar in principle
to the high-deductible health plans that
are currently a predominant commercial
health insurance arrangement in the U.S.
Like Part D, the high-deductible plans are
designed to encourage the use of appro-
priate medical services and discourage
discretionary care in a bid to ensure good
health outcomes, while controlling health
carespending(13).However, suchdesigns
have been shown to delay or discourage
crucial care, leading to poor health out-
comes. For example, several studies have
shown that entering the coverage gap
and being exposed to high out-of-pocket
costs for medications negatively impact
patients’ drug use overall and potentially
their clinical outcomes (14–17). While
the Part D coverage gap closed in 2020,
understanding the relationship between
high out-of-pocket costs and resource
use is still highly relevant given rising
drug list prices (on which coinsurance is
calculated) and trends in health plans
requiring greater cost sharing from
patients.
Using the 2016 Medicare Part D cov-
erage gap as an example, we explored the
effects of increased out-of-pocket costs
on adherence to branded dipeptidyl pep-
tidase 4 inhibitors (DPP-4i) in Medicare
beneficiaries without low-income subsi-
dies (approximately two-thirds of Medi-
care beneficiaries) relative to patients
with full subsidies who are not affected
by the steep increases in out-of-pocket
expenses during the coverage gap. Fur-
ther, among patients who discontinued
and then reinitiated treatment, we ex-
plored seasonality in reinitiation because
we hypothesized that patients are more
likely to reinitiate in January when ben-
efits reset and out-of-pocket costs are
lower (18). We used two levels of con-
trols. The first was Medicare beneficia-
ries with full financial subsidies, where
qualifying individuals have a zero/fixed
small copayment throughout the year
and health care use is unaffected by
increased out-of-pocket costs. As a sec-
ond control, to isolate cost-related ad-
herencechanges,werepeatedall analyses
separately in patients initiating sulfonyl-
ureas, the most widely used, low-cost
generic antidiabetic drugs (19).
RESEARCH DESIGN AND METHODS
Study Design, Setting, and Participants
This was a retrospective cohort study
using a 20% random sample of theMedi-
care claims data. The Centers for Medi-
care and Medicaid Services provides
research-identifiable data sets with 5%
and 20% samples of beneficiaries to
groups conducting research. We first
identified DPP-4i or sulfonylurea initia-
tors from the random sample of Medi-
care beneficiaries aged $66 years with
fee-for-service Part A, B, and D enroll-
ment in at least 1 month during the
calendar years 2015 and 2016. We re-
quired participants to initiate either a
DPP-4i or a sulfonylurea in 2015 after a
6-month washout period without use of
the drug of interest. From these groups,
we selected patients who filled at least
one prescription of the index drug in
2016 and entered the 2016 coverage gap.
DPP-4i and sulfonylurea initiators were
both stratified into those with no low-
income subsidy (hereafter referred to as
nonsubsidized patients) and those with
full low-income subsidy benefits (re-
ferred to as subsidized patients). Patients
with partial low-income subsidy and
employer-sponsored coverage were ex-
cluded because the Part D data do not
include information on the level of mon-
etary support,whichmakes themedication
uptakebehaviors systematically different
from the nonsubsidized or the fully sub-
sidized beneficiaries.
Primary Variables
Our primary outcomes of interest were
medication adherence and time to reini-
tiation. Adherence was measured as the
proportion of days covered (PDC) before
andafterentry into thecoveragegapusing
data fields on prescription refills and days’
supply. PDCwas calculated as the number
of days’ supply for the study drug class in a
certain period (pre- or postcoverage gap
period in 2016), divided by the number of
days in that period. Being adherent was
definedasPDC$0.80,awidelyusedcutoff
in the literature (20). Reinitiation was
captured as a new fill for a drug in the
class of interest after a period of discon-
tinuation ($60 days without the drug
after the end of the days’ supply of the
previous prescription).
Statistical Analyses
We used a difference-in-difference (DiD)
multivariable Poisson regression analysis
to measure the effect of entering the
coverage gap on medication adherence,
evaluating the probability of being ad-
herent to DPP-4i (i.e., PDC $0.80) (20).
The DiD model compared changes in ad-
herence before and after entering the
coverage gap for patients whose out-of-
pocket costs are likely to increase in the
coverage gap (nonsubsidized) versus pa-
tients whose out-of-pocket costs remain
low and fixed across benefit phases (sub-
sidized). The true coverage gap effect from
DiDmodels is thedifference inadherence
between the subsidized and nonsubsidized
groups in the coverage gap, after subtract-
ing the difference between the subsidized
andnonsubsidized groupsbefore entering
the coverage gap.
All models were adjusted for demo-
graphics, comorbidities, including the
Charlson comorbidity index (CCI), and
the number of unique drugs prescribed.
We defined the CCI and comorbidities
using ICD-9 and ICD-10 diagnosis codes
(Supplementary Table 2) and calculated
the number of unique drugs based on the
number of distinct generic names found
in thepharmacy claims.Wedefinedentry
into the coverage gap and the catastrophic
phase as the earliest date on which a ben-
eficiary had any pharmacy claim on which
the benefit phase variable indicated entry
into or, for the coverage gap, a transition to
the next benefit phase. We used pharmacy
claims to identify medication costs.
We expect baseline characteristics to
differ between subsidized and nonsub-
sidized patients; thus, a conventional
table comparing baseline covariates is
not intended to convey covariatebalance
like in the case of randomized trials or
cohort studies (21). However, the critical
assumption in DiD analyses is that the
differences between groups are stable
over time, which is reasonable in this
setting because the differences between
subsidized and nonsubsidized patients
are not expected to vary considerably
over 1 calendar year. While it is not
necessary to adjust for covariates in
DiD analyses (crude and adjusted results
tend to be very close), we report both
estimates in keepingwith recommended
best practices (21).
Next, among patients who discontin-
ued index treatment during follow-up
(irrespective of whether they entered
the coverage gap or not), we assessed
the time to reinitiation by monitoring
patients from the discontinuation date
until reinitiation, death, or the end of the
study period (31 December 2016). Using
Cox proportional hazard models, we as-
sessed the hazard ratios (HRs) of reini-
tiation of the index therapy during each
calendar month from July 2015 to June
2016, relative to January 2016, sepa-
rately for beneficiaries with and without
subsidies. All models included indicator
variables for each calendar month, de-
mographics, comorbidities, and theunique
count of prescription medications as co-
variates. All of the above adherence and
reinitiation analyses were repeated sepa-
rately among sulfonylurea initiators who
face limited out-of-pocket costs and serve
as a negative control.
We used the Strengthening the Report-
ing of Observational Studies in Epidemiol-
ogy (STROBE) reporting recommendations
for cohort studies to describe details of




For DPP-4i, there were 11,594 subsidized
initiators and 12,797 nonsubsidized
initiators in 2015. Of these, 8,096 sub-
sidized patients (69.8%) and 6,173 non-
subsidized patients (48.2%) filled at least
one prescription of a DPP-4i in 2016 and
entered the 2016 coverage gap. For
sulfonylureas, 6,183 of 14,093 subsidized
initiators (43.9%) and 5,082 of 20,618
nonsubsidized initiators (24.6%) filled at
least one sulfonylurea prescription in
2016 and entered the 2016 coverage gap.
Descriptive Data
For both drugs, the subsidized group
tended to be predominantly nonwhite
and women; in contrast, nonsubsidized
patients were predominantly white and
approximately half were men (Table 1).
The subsidized patients were also gen-
erally sicker (meanCCI score;5 inDPP-4i
and sulfonylurea groups) than nonsub-
sidized patients (mean CCI score ;4 in
DPP-4i and sulfonylurea groups). Among
nonsubsidized DPP-4i initiators, the av-
erage out-of-pocket payment per DPP-4i
prescription filled during the coverage
gap in 2016 was $227, compared with
only $11 per sulfonylurea prescription
filled during the coverage gap. As ex-
pected, the differences were minimal
for subsidized patients (per-prescription
cost of $3 for DPP-4i and $1 for sulfo-
nylurea filled during the coverage gap).
Adherence
Figure 1 and Table 2 present the DiD
analysis results. Among nonsubsidized
DPP-4i initiators, more patients were
adherent before entering the coverage
gap than after, resulting in a difference
of219.4 percentage points. Among sub-
sidized DPP-4i initiators, the correspond-
ing difference was only22.5 percentage
points. After subtracting thedifference in
adherence among subsidized patients,
the effect of facing higher costs reduced
adherence of nonsubsidized patients by
16.9% (adjusted DiD 216.9%; 95%
CI 218.7%, 215.1%). In contrast, the
difference in the proportion of sulfonyl-
urea initiators being adherent before and
after entering the coverage gap was
similar in the nonsubsidized and sub-
sidized patients (adjusted DiD 21.6%;
95% CI 23.4%, 0.2%; adjusted relative
risk 0.98; 95% CI 0.95, 1.01). Sensitivity
analyses in patients restricted to those
who entered the coverage gap but not
the catastrophic phase in 2016 also
yielded similar results (Supplementary
Table 1).
Reinitiation
Among patients initiating DPP-4i in 2015,
10,456 of the nonsubsidized patients
(82%) and 7,462 of the subsidized pa-
tients (64%) discontinued treatment dur-
ing follow-up (Supplementary Table 3).
The median time to discontinuation was
121 days among nonsubsidized patients
and 151 days among subsidized patients.
Of those who discontinued, 44% of the
nonsubsidized patients and 51% of the
subsidized patients reinitiated treatment
during follow-up. Figure 2 demonstrates
the monthly HRs of reinitiation of the
discontinued drugs from July 2015 to
June 2016, relative to January 2016,
for nonsubsidized and subsidized DPP-
4i initiators, separately. Relative to Jan-
uary 2016, for nonsubsidized DPP-4i pa-
tients the HR of reinitiation was lower in
the months leading up to January when
the benefit structure resets, with the
lowest HR in December 2015 (HR ;0.5;
95% CI 0.6, 0.4). In the same population,
the HR of reinitiation was also relatively
lower inFebruaryandgraduallydecreased
over the next few months, but the mag-
nitudes were much lower than the mag-
nitudesobserved in the last fewmonthsof
the calendar year. For the subsidizedDPP-
4i patients, the monthly HR of reinitiation
varied minimally by month and was at
times slightly higher relative to January
2016. Among the sulfonylurea initiators,
however, theHRsof reinitiation relativeto
January 2016 were similar for the non-
subsidized and subsidized groups with
overlapping CIs and no strong temporal
pattern. While the HRs for reinitiation in
thenonsubsidizedgroupwerestill lower in
the last few calendar months, the magni-
tudes were much lower than those ob-
served in the case of DPP-4i (Fig. 2).
CONCLUSIONS
Our results clearly demonstrate that facing
increased out-of-pocket costs (in this case
due to entry into the coverage gap) neg-
atively affects adherence and reinitiation
of branded, relatively expensive antihy-
perglycemic drugs among patients with-
out financial subsidies.We also observed
that patients who discontinued branded
antihyperglycemic medications were likely
to wait until January to reinitiate discon-
tinued drugs, at a time when the benefit
structure resets. Both of these outcomes
are particularly relevant for diabetes,
because decreased adherence or delay-
ing treatment reinitiation may increase
morbidity, mortality, and additional health
care costs (3–7). The above associations
were not present for sulfonylureas, which
are low-cost generics therapeutically equiv-
alent to DPP-4i (23), highlighting that low
out-of-pocket costs do not affect adher-
ence/reinitiation.
Despite the coverage gap being re-
duced to 25% coinsurance beginning in
2019, these results are relevant given the
growth indrug list prices over time inPart
D and recent increased enrollment in
employer-mandated high-deductible com-
mercial health insurance plans. For the
latter,suchplansrequirehighout-of-pocket
payments (annually $1,000–$7,000 per pa-
tient). Although the timing of the out-of-
pocket payment is different from that in
the coverage gap, the burden of high cost
sharing under such plans is similar in prin-
ciple to that faced by nonsubsidized
beneficiaries under Medicare Part D.
Recent studies demonstrated that low-
income patients with diabetes in high-
deductible plans have increased emergency
department visits for diabetes complica-
tions and are likely to delay seeking care
for macrovascular complications compared
with patients in low-deductible plans
(13). The subsidized control patients in
our study are analogous to thepatients in
low-deductible plans whose health care
use isunlikely tochange in response toout-
of-pocket costs. Recent efforts such as the
“Choosing Wisely campaign” (24) have
discussed reducing low-value care to avoid
unnecessary health care use and reduce
costs, but our study, along with the rele-
vant literature, suggests that increasing
cost sharing as a means to reduce low-
valuecarepresentsabarrier toappropriate
care, particularly in chronic conditions.
In 2016, nonsubsidized patients paid
45% coinsurance out-of-pocket during
the coverage gap. Among the nonsubsi-
dized DPP-4i initiators in our study, this
amounted to an average out-of-pocket
payment of $227 for every 30-day DPP-4i
prescription filled during the coverage
gap. With the coinsurance reduced to
25% since 2019 with elimination of the
coverage gap, nonsubsidized patients
will still have to pay ;$126 per DPP-4i
prescription (;$1,500 annually), a po-
tential affordability problem for many
patients. Moreover, the absolute out-
of-pocket payment increases with an in-
crease in drug prices, imposing a substantial
financial burden on patients and resulting
in decreased adherence and adverse
health outcomes downstream.
The negative association between the
coverage gap and adherence in our study










sulfonylureasn 5 6,173 n 5 8,096 n 5 5,082 n 5 6,183
Age mean (SD), years 74.7 (6.83) 73.0 (9.60) 0.202 74.1 (6.92) 71.4 (10.13) 0.31
Sex, male, n (%) 3,154 (51.1) 2,654 (32.8) 0.432 2,738 (53.9%) 2,136 (34.5%) 0.432
Race, n (%)
White 5,515 (89.3) 4,421 (54.6) 0.472 4,583 (90.2) 3,501 (56.6) 0.449
Black 317 (5.1) 1,790 (22.1) 1.087 302 (5.9) 1,580 (25.6) 1.082
Other 341 (5.5) 1,885 (23.3) 1.077 197 (3.9) 1,102 (17.8) 1.118
Baseline CCI score, mean (SD) 4.1 (2.70) 4.8 (2.76) 0.249 4.3 (2.69) 5.0 (2.80) 0.221
Comorbidities, n (%)
Retinopathy 810 (13.1) 1,343 (16.6) 0.24 702 (13.8) 984 (15.9) 0.146
Nephropathy 778 (12.6) 1,169 (14.4) 0.141 641 (12.6) 851 (13.8) 0.091
Neuropathy 1,287 (20.8) 2,382 (29.4) 0.343 1,165 (22.9) 1,834 (29.7) 0.259
Hyperlipidemia 5,279 (85.5) 6,679 (82.5) 0.036 4,323 (85.1) 4,989 (80.7) 0.053
Atherosclerosis 2,755 (44.6) 3,858 (47.7) 0.066 2,487 (48.9) 3,104 (50.2) 0.026
Myocardial infarction 95 (1.5) 159 (2.0) 0.364 94 (1.8) 112 (1.8) 0.031
Stroke 464 (7.5) 898 (11.1) 0.399 402 (7.9) 717 (11.6) 0.391
Chronic kidney disease 2,008 (32.5) 3,070 (37.9) 0.155 1,781 (35.0) 2,361 (38.2) 0.087
Number of drugs prescribed,
mean (SD) 13.2 (5.76) 17.6 (7.81) 0.636 14.4 (5.89) 18.3 (7.53) 0.584
Number of prescriptions in the
2016 coverage gap
DPP-4i prescriptions, mean (SD) 1.8 (2.05) 2.4 (2.31) 0.240 0.6 (1.40) 0.7 (1.59) 0.116
Sulfonylurea prescriptions,
mean (SD) 0.9 (1.59) 0.8 (1.65) 0.037 1.7 (1.77) 2.1 (2.10) 0.205
Patient pay amount in the
2016 coverage gap
Per DPP-4i prescription,
mean (SD), $ 227.3 (144.48) 3.7 (8.39) 2.186 237.0 (151.27) 3.6 (2.53) 2.182
Per sulfonylurea prescription,
mean (SD), $ 11.4 (15.00) 1.3 (1.02) 0.949 9.8 (15.31) 1.3 (1.14) 0.783
Number of prescriptions (any drug)
In 2016, mean (SD) 51.2 (36.54) 79.2 (67.40) 0.517 48.9 (39.03) 74.2 (68.45) 0.455
During the 2016 coverage gap,
mean (SD) 18.8 (16.97) 23.7 (20.98) 0.258 15.9 (17.37) 22.1 (24.07) 0.297
Nonsubsidized patients, patients without low-income subsidy. Subsidized, patients with low-income subsidy. The 2016 coverage gap began once
patients reached the plan’s initial coverage limit of $3,310 and endedwhen a total of $4,850was spent in 2016. During the coverage gap, patients were
responsible for 45% of the cost of brand-name drugs. SMD, standardized mean difference.
is consistent with a previous study that
found patients with no or generic-only
coverage in the coverage gap were less
likely to be adherent to antihyperglyce-
mic treatment after entering the gap in
2008 (14). This previous study assessed
adherence to any antihyperglycemic
treatmentwithoutdistinguishing individ-
ual drug classes thatdifferwith respect to
pricing and brand/generic market pen-
etration and that represent a range
of diabetes control, all of which can
influence the response to changes in
copayment in the coverage gap. A
strength of our study is that it explored
this question using a more recent year
of data (2016), after the Affordable
Care Act was passed, and used two
levels of controls to isolate the effect
of high out-of-pocket costs. One was
comparing DPP-4i patients without
subsidies to a control group of DPP-
4i patients with low-income subsidies
that protected the latter group from
steep increases in out-of-pocket costs
during the coverage gap. The second
was separately repeating all analyses in
patients initiating sulfonylureas, which
are low-cost alternatives to DPP-4i (25).
Without directly comparing DPP-4i to
sulfonylurea patients in the same anal-
ysis, this approach confirmed thehypoth-
esis that due to the low out-of-pocket
payment for sulfonylureas during the
coverage gap, no substantial changes
in adherence before and after the donut
hole exist for both patients with and
without financial subsidies. Similarly,
we did not observe strong temporal
patterns for reinitiation among sulfonyl-
urea patients.
Ours is the first study to demonstrate
howout-of-pocketpayments forpatients
with diabetes influence the decision
to reinitiate discontinued, branded
antihyperglycemic medications at the
beginning of the calendar year, thereby
illustrating forward-looking behavior of
patients within a narrow time span. This
is inagreementwithaprevious study that
observed reduced monthly medication
adherence as the calendar year pro-
gressed in response to the donut hole
in 2009 (26). It is also interesting to note
thatwhile no strong temporal patterns of
reinitiation were observed for sulfony-
lureas, the HRs of reinitiation among
nonsubsidized patients were still lower
in the last few calendar months of the
year. While the magnitudes were much
lower for sulfonylureas than those ob-
served in the case of DPP-4i, this implies
that being in the coverage gap made
patients less likely to fill all medications,
although there is a much stronger tem-
poral effect for the more expensive
medications.
The results from the current study,
based on data from 2016, also provide
relevant design and analytic considera-
tions for pharmacoepidemiology studies
assessing the comparative safety and
effectiveness of antihyperglycemic drugs
using real-world Medicare claims data. A
major critique of observational explora-
tion of antihyperglycemic drug use in
Medicare data is the short time on
treatment, which makes it harder to
evaluate long-term outcomes. Between
64% and 82% of DPP-4i initiators in our
Figure 1—DiD analysis comparing changes in adherence before and after entering the coverage
gap in 2016 between subsidized and nonsubsidized patients. SU, sulfonylurea.
Table 2—Results from DiD analyses for the association between the coverage gap and being adherent (PDC ‡0.8) for DPP-4i
and sulfonylurea initiators who entered the coverage gap in 2016
% with PDC $0.8
before coverage gap
% with PDC $0.8 while
in coverage gap
Difference (in coverage
gap 2 before coverage gap) Relative risk (95% CI)
DPP-4i
Nonsubsidized
patients 68.4 (66.9, 69.8) 49.0 (47.5, 50.5) 219.4 (220.8, 218.0)
Subsidized patients 73.2 (72.1, 74.3) 70.7 (69.6, 71.8) 22.5 (23.6, 21.4)
Coverage effect 216.9 (218.7, 215.1) 0.76 (0.74, 0.78)
Sulfonylureas
Nonsubsidized
patients 68.4 (66.8, 70.1) 60.4 (58.6, 62.1) 28.1 (29.4, 26.8)
Subsidized patients 68.4 (67.2, 69.7) 62.0 (60.7, 63.3) 26.4 (27.7, 25.2)
Coverage effect 21.6 (23.4, 0.2) 0.98 (0.95, 1.01)
PDC calculated as the number of days’ supply for the drug class in a certain period (pre- or postcoverage gap period in 2016), divided by the number of
days in that period. All models adjusted for age, sex, race, and comorbidities. Nonsubsidized patients, patientswithout low-income subsidy. Subsidized
patients, patients with full low-income subsidy.
study, regardless of financial subsidies,
discontinued treatment, with a median
time to discontinuation 121–151 days,
but approximately half of those who
discontinued reinitiated treatment. This
implies that cost/benefit structures influ-
ence the adherence and reinitiation pat-
terns, which in turn can influence time
on treatment, and methods to accurately
measure drug exposure (e.g., updating
exposure time) inpharmacoepidemiology
studies should be considered.
Limitations
Our study should be interpreted in light
of the following caveats. First, insurance
claims data do not contain information
on whether patients are actually taking
themedications as prescribed. Behaviors
such as taking medications every other
day or cutting doses in half to delay the
refillmayoccur, especially for thoseusing
cost-saving strategies. The outcome of
adherence in our study defined as PDC
usingdata onprescription refills and days
supplied was, therefore, only a proxy for
the actual adherence. The degree of
inaccuracy in measurement is expected
to be uniform in the periods before and
after entering the coverage gap, and
therefore, this limitation is not expected
to significantly affect our conclusions.
Second, while we examined the associ-
ation between the coverage gap and
adherence, we could not examine the
impact of the coverage gap on clinically
important parameters such as HbA1c,
because these data are not available
inMedicare claims. Third, themagnitude
of differences observed in this study
may not be applicable to other classes of
antihyperglycemic drugs or patients
with more severe disease. Finally, this
study was not designed to assess asso-
ciations between cost-related nonadher-
ence or delayed reinitiation and long-term
health outcomes, but future studies
should explore the impact of these on
mortality, amputations, and other out-
comes of interest.
Conclusion
Using the example of 2016Medicare Part
D coverage gap, our study demonstrates
that increased out-of-pocket costs are
associated with poor adherence and
delayed reinitiation in patients without
financial subsidies for commonly used,
brandedantihyperglycemic drugs. Despite
the Part D gap being reduced to 25%
coinsurance beginning in 2019, these re-
sults remain relevant, because prices for
branded drugs increase over time and a
growing number of patients are exposed
to high cost sharing on commercial plans.
This is particularly relevant for patients
with chronic diseases, such as diabetes,
where decreased treatment adherence or
health care usemay result in downstream
negative health outcomes.
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